Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Absci, Faire, and 370+ companies. 5-min read every Tuesday.
Absci uses generative AI to design de novo antibodies and protein therapeutics from scratch — enabling the design of entirely new drug candidates in weeks instead of the traditional multi-year discovery process. Valued at $2.3B with $250M raised, Absci has partnerships with major pharmaceutical companies including Merck and is advancing multiple AI-designed therapeutic candidates toward clinical trials. Major AI biotech IPO candidate as generative protein design transforms drug discovery into an engineering problem.
| Industry | Biotechnology |
| Stage | Series C |
| IPO Status | Private |
| Valuation | $2.3B |
| Total Funding | $225M |
| Headquarters | Vancouver, WA |
Faire is the wholesale marketplace connecting 700K+ independent retailers with 100K+ emerging brands — the B2B commerce platform for the indie retail economy. Valued at $12.4B with $1.7B raised, Faire processes billions in annual GMV and is the dominant wholesale marketplace globally. IPO candidate as B2B commerce digitisation continues to disrupt traditional wholesale distribution — a $50B+ global market.
| Industry | E-commerce |
| Stage | Series H |
| IPO Status | Private |
| Valuation | $12.4B |
| Total Funding | $1.7B |
| Headquarters | San Francisco, CA |
Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.
Or buy any single company report for $19
Absci is valued at $2.3B. Faire is valued at $12.4B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.
Absci is currently private. Faire filed an S-1 in April 2026 and is actively in the IPO pipeline. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.
Absci has raised $225M. Faire has raised $1.7B.
Absci operates in Biotechnology, while Faire operates in E-commerce.
Absci is a Biotechnology company valued at $2.3B with $225M raised. Faire is a E-commerce company valued at $12.4B with $1.7B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.
Accredited investors can access pre-IPO shares in Absci and Faire through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.